First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced metastatic castration resistant prostate cancer patients: promising antitumor effect in advanced mCRPC even after failure of prior 177Lu-PSMA treatment with tolerable side effects.
Read more>>
Other news & events
- News04.12.2025
#BlueNovemberWithRadiotheranostics for Urologists, Oncologists and Nuclear Medicine physicians
Read more - News10.11.2025
#BlueNovemberWithRadiotheranostics - The VISION trial: Meet Dr Alison Armour
Read more - News06.11.2025
Oncidium Foundation USA Achieves 501(c)(3) Status to Expand Patient Access to Nuclear Medicine and Theranostics
Read more
